Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy

J Antimicrob Chemother. 2018 May 1;73(5):1256-1262. doi: 10.1093/jac/dky028.

Abstract

Objectives: Antibiotic selective pressure may result in changes to antimicrobial susceptibility throughout the course of infection, especially for organisms that harbour chromosomally encoded AmpC β-lactamases, notably Enterobacter spp., in which hyperexpression of ampC may be induced following treatment with cephalosporins. In this study, we document a case of bacteraemia caused by a blaSME-1-harbouring Serratia marcescens that subsequently developed resistance to expanded-spectrum cephalosporins, piperacillin/tazobactam and fluoroquinolones, over the course of several months of treatment with piperacillin/tazobactam and ciprofloxacin.

Methods: Susceptibility testing and WGS were performed on three S. marcescens isolates from the patient. β-Lactamase activity in the presence or absence of induction by imipenem was measured by nitrocefin hydrolysis assays. Expression of ampC and blaSME-1 under the same conditions was determined by real-time PCR.

Results: WGS demonstrated accumulation of missense and nonsense mutations in ampD associated with stable derepression of AmpC. Gene expression and β-lactamase activity of both AmpC and SME-1 were inducible in the initial susceptible isolate, but were constitutively high in the resistant isolate, in which total β-lactamase activity was increased by 128-fold.

Conclusions: Although development of such in vitro resistance due to selective pressure imposed by antibiotics is reportedly low in S. marcescens, our findings highlight the need to evaluate isolates on a regular basis during long-term antibiotic therapy.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy
  • Bacterial Proteins / metabolism*
  • Ciprofloxacin / adverse effects
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use
  • Gene Expression Profiling
  • Humans
  • Microbial Sensitivity Tests
  • Middle Aged
  • Piperacillin, Tazobactam Drug Combination / adverse effects
  • Piperacillin, Tazobactam Drug Combination / pharmacology
  • Piperacillin, Tazobactam Drug Combination / therapeutic use
  • Real-Time Polymerase Chain Reaction
  • Selection, Genetic*
  • Serratia Infections / drug therapy*
  • Serratia marcescens / drug effects*
  • Serratia marcescens / enzymology
  • Whole Genome Sequencing
  • beta-Lactam Resistance*
  • beta-Lactamases / metabolism*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Piperacillin, Tazobactam Drug Combination
  • Ciprofloxacin
  • beta-lactamase Sme-1
  • AmpC beta-lactamases
  • beta-Lactamases